Compare BridgeBio Pharma Inc (BBIO) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs EPAM Systems Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while EPAM Systems Inc trades at $99.47 (market cap $5.02B). The key difference: BridgeBio Pharma Inc is far larger — about 3.3× EPAM Systems Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | EPAM | |
|---|---|---|
Market Cap | $16.61B | $5.02B |
Sector | Health | Technology |
52-Week High | $90.17 | $221.40 |
52-Week Low | $47.29 | $76.04 |
Enterprise Value | $18.16B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EPAM Systems trades at $97.43, up 4.68% today, but faces bearish technical signals with resistance at $99. The company delivered strong Q2 2026 earnings beats with EPS of $3.38 versus $3.16 expected, though revenue guidance was lowered due to slower North American growth. Valuation metrics appear attractive with P/E of 13.22 and P/S of 0.94, while profitability remains solid with 7.15% net margin.
Despite near-term headwinds, EPAM's partnership with OpenAI and strong AI-native revenue growth provide long-term catalysts. Risks include software services demand softness and competitive pressures. Analyst consensus remains bullish with $117.27 price target (20% upside), though investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
